Universal Cells
Mark Orr has a wealth of experience in translational research immuno-oncology and cellular therapy. Mark has held various roles at companies such as Universal Cells, Bristol Myers Squibb, Celgene, and HDT Bio Corp. Mark's expertise includes managing research teams, developing new therapies, identifying biomarkers, and leading vaccine development projects. Mark has a strong background in immunology, with a PhD from the University of Washington School of Medicine. Mark has also taught courses on vaccine adjuvants and has received grants from prestigious organizations like the NIAID and the CDC.
Universal Cells
Universal Cells is a Seattle-based biotech developing, licensing and commercializing stem cell therapies that overcome immune rejection and can be used to create true off-the-shelf therapeutic products. Using the company's proprietary genome editing approach, the company engineers stem cells to prevent expression of polymorphic human leukocyteantigen (HLA) molecules, removing the cause of donor tissue rejection and creating Universal Donor Stem Cells that are compatible with every patient.